Critical Limb Ischemia - Pipeline Review, Q4 2010

Global Markets Direct, December 2010, Pages: 44

Critical Limb Ischemia - Pipeline Review, Q4 2010

Summary

Global Markets Direct’s, “Critical Limb Ischemia Pipeline Review, Q4 2010”, provides an overview of the Critical Limb Ischemia therapeutic pipeline. This report provides information on the therapeutic development for Critical Limb Ischemia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Critical Limb Ischemia. “Critical Limb Ischemia-Pipeline Review 2010, Q4 2010” is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- A snapshot of the global therapeutic scenario for Critical Limb Ischemia.
- A review of the Critical Limb Ischemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Critical Limb Ischemia pipeline on the basis of therapeutic class, route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Critical Limb Ischemia.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Critical Limb Ischemia pipeline depth and focus of Critical Limb Ischemia therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Critical Limb Ischemia Overview
Therapeutics Development
An Overview of Pipeline Products for Critical Limb Ischemia
Critical Limb Ischemia Therapeutics under Development by Companies
Critical Limb Ischemia Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Pre-Clinical Stage Products
Comparative Analysis
Companies Involved in Critical Limb Ischemia Therapeutics Development
Aastrom Biosciences, Inc.
Sanofi-Aventis
medac GmbH
MultiGene Vascular Systems (MGVS) Ltd.
TCA Cellular Therapy
Pluristem Therapeutics Inc.
LTT Bio-Pharma Co., Ltd.
Viromed Co., Ltd.
Universities/Institutes Involved in Critical Limb Ischemia Therapeutics Development
Critical Limb Ischemia Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Late Stage Drug Profiles – Companies
AS-013 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Temusi - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Urokinase - Drug Profile
Product Description
Mechanism of Action
R&D Progress
XRP0038 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Late Stage Drug Profiles – Universities/Institutes
Autologous bone marrow cell concentrate transplantation - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Critical Limb Ischemia - Featured News
Oct 20, 2010: Aastrom Submits Special Protocol Assessment To FDA for Its Phase 3 CLI Program
Oct 18, 2010: Aastrom Receives FDA Fast Track Designation for Phase 3 CLI Program
Sep 22, 2010: Sanofi-Aventis Reports Phase III Trial Update On NV1FGF For Treatment Of Critical Limb Ischemia
Sep 14, 2010: Pluristem Reports Clinical Trials Data Of PLX-PAD In Patients With Critical Limb Ischemia
Jul 06, 2010: Aastrom To Pursue Phase III Clinical Program In Critical Limb Ischemia
Mar 25, 2010
Sep 17, 2008: PLX-PAD Could Become An Effective Therapeutic Alternative For Diabetics, Smokers And Others Who Are At Risk Of Amputation
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

Customers who bought this item also bought

• The Stem Cell Market Outlook
• Nitric Oxide - Therapeutics, Markets and Companies
• Regenerative Medicine Markets
• Biomet Profile (Biomaterials): Global Market Share Analysis by region, SWOT, Product Pipeline & Financials 2012
• Nausea – Pipeline Review, H1 2013
• Drug Addiction – Pipeline Review, H1 2013
• Substance (Drug) Abuse – Pipeline Review, H1 2013
• Textbook of Peripheral Vascular Interventions. Edition No. 2
• Psychosis – Pipeline Review, H1 2013
• HIV / AIDS – Pipeline Review, H1 2013